Clinical Trial Update: PI3K Inhibitor BKM120, Carboplatin, and Pemetrexed Disodium in Treating Patients With Stage IV Non-Small Cell Lung Cancer [Phase 1]

View source ↗

Summary

This update reports on a Phase 1 trial evaluating the PI3K inhibitor BKM-120 (buparlisib) in combination with carboplatin and pemetrexed for stage IV non-small …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• BKM-120 (buparlisib)
• CARBOPLATIN (Carboplatin)
• Pemetrexed disodium (Pemetrexed disodium)

Snippet

Sponsor: City of Hope Medical Center | Conditions: Recurrent Non-small Cell Lung Cancer, Stage IV Non-small Cell Lung Cancer | Phase 1 | Status: COMPLETED